Rehabilitation Robotic System ReHand

Not Applicable

Completed

Conditions: Stroke
Rehabilitation
Robotic Exoskeleton

Registration Number: NCT06937346

Lead Sponsor: Karaganda Medical University

Brief Summary: The aim of this clinical trial is to investigate the efficacy of the ReHand rehabilitation system for the recovery of patients after a stroke.

The main objectives of the study:

1. To assess the functional state of patients with cerebral stroke according to the The Barthel Index, on the Functional Independence Measure (FIM) scale of functional independence.

2. To assess the neurological deficit of patients according to the National Institutes of Health Stroke Scale (NIHSS), the state of function of the affected arm and the degree of fine motor impairment according to the The Frenchay Arm Test (FAT), The Fugl-Meyer Assessment for upper extremity (FMA-UE) scale, modified Wolf Motor Function Test (mWMFT), according to the upper limb disability questionnaire The Disabilities of the Arm, Shoulder, and Hand (DASH) test.

3. To investigate the state of psycho-emotional status in patients on the Hospital Anxiety and Depression Scale (HADS) of anxiety and depression.

4. To determine the effectiveness of the rehabilitation performed in patients with cerebral stroke after recovery by the ReHand system according to the above scales.

Participants:

All patients received standard rehabilitation methods according to the clinical protocol for diagnosis and treatment No. 94, "The third stage of medical rehabilitation", approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan on May 14, 2020.

The main group of patients underwent rehabilitation using a robotic glove for 8 weeks, with 5 classes per week and each class lasting 45 minutes.

The control group did not receive robotic glove-based rehabilitation.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 120

Inclusion Criteria

a stroke that occurred no more than six months prior;
absence of somatic conditions that would interfere with the use of the hand exoskeleton system (such as rheumatoid arthritis, severe muscle hypertonia, joint pathology, fractures, etc.);
clear consciousness;
presence of upper limb and fine motor impairments;
no history of recurrent cerebral strokes;
no comorbidities associated with cognitive dysfunction (such as Parkinson's disease, Wernicke's encephalopathy, alcoholic encephalopathy, etc.) that would hinder instruction comprehension;
absence of rheumatological issues (including contractures and significant pain syndromes) that would impede study participation;
absence of acute or chronic (in the decompensated stage) diseases of internal organs;
signing of informed consent for study participation;
all participants were adults

Exclusion criteria:

lack of clear consciousness,
a history of recurrent cerebral stroke,
a stroke that occurred more than 6 months ago,
lack of upper limb function or fine motor disorders,
the presence of concomitant diseases associated with cognitive dysfunction (such as Parkinson's disease, Wernicke encephalopathy, alcoholic encephalopathy, etc.) that may interfere with understanding the instructions,
rheumatological diseases.
problems (including contractures and severe pain syndromes) that could interfere with participation in the study,
the presence of acute or chronic (decompensation stage) diseases of internal organs,
contraindications according to Clinical Protocol No. 94 on diagnosis and treatment "The third stage of medical rehabilitation", approved by the Ministry of Health of the Republic of Kazakhstan on May 14, 2020 (frequent or severe bleeding of various origins; febrile or subfebrile fever of unknown origin; acute infectious diseases; acute osteomyelitis; acute deep vein thrombosis; complicated cardiac arrhythmias, heart failure in the active stage; active forms of tuberculosis; malignant tumors (IV clinical group).; respiratory failure of stage III and above; various purulent (pulmonary) diseases with significant intoxication; decompensated diseases such as irreversible metabolic disorders (diabetes mellitus, myxedema, thyrotoxicosis, etc.), functional insufficiency of the liver or pancreas of stage III; epilepsy in the seizure phase; mental disorders causing desocialization and emotional or behavioral disorders.; purulent skin diseases, infectious skin diseases (scabies, fungal infections, etc.); anemia with an Hb level of 90 g/l or lower;
lack of signed informed consent to participate in the study.;
he underage age of the participants.

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)	60 days later	Fugl-Meyer Assessment for Upper Extremity (FMA-UE); range: 0-66 points; higher scores indicate better motor function and less impairment.

Secondary Outcome Measures

Name	Time	Method
Barthel Index (BI)	60 days later	Barthel Index; range: 0-100 points; higher scores indicate greater independence in activities of daily living.
Functional Independence Measure Scale (FIM)	60 days later	Functional Independence Measure (FIM); range: 18-126 points; higher scores indicate greater functional independence.
National Institutes of Health Stroke Scale (NIHSS)	60 days later	National Institutes of Health Stroke Scale (NIHSS); range: 0-42 points; higher scores indicate more severe neurological impairment.
Frenchay Arm Test	60 days later	Frenchay Arm Test (FAT); range: 0-5 points; higher scores indicate better arm function.
Modified Wolf Motor Function Test (mWMFT)	60 days later	modified Wolf Motor Function Test (mWMFT); total score range: 0-75 points; higher scores indicate better upper extremity motor function.
Disabilities of the Arm Shoulder, and Hand (DASH) Test	60 days later	Disabilities of the Arm, Shoulder and Hand (DASH); range: 0-100 points; higher scores indicate greater disability.
Hospital Anxiety and Depression Scale (HADS)	60 days later	Hospital Anxiety and Depression Scale (HADS); range: 0-42 points; higher scores indicate greater psychological distress (more severe anxiety and depression symptoms).